A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19.

ABSTRACT: The Seraph100 Microbind Affinity Blood Filter (Seraph 100) (ExThera Medical, Martinez, CA) is an extracorporeal therapy that can remove pathogens from blood, including severe acute respiratory syndrome coronavirus 2. The aim of this study was to evaluate safety and efficacy of Seraph 100 treatment for COVID-19.

Design

Retrospective cohort study.

Setting

Nine participating ICUs.

Patients

COVID-19 patients treated with Seraph 100 (n = 53) and control patients matched by study site (n = 53).

Intervention

Treatment with Seraph 100.

Measurements and main results

At baseline, there were no differences between the groups in terms of sex, race/ethnicity, body mass index, and need for mechanical ventilation. However, patients in the Seraph 100 group

SUBMITTER: Chitty SA 

PROVIDER: S-EPMC9049035 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature